EMA Authorised: Rezdiffra (resmetirom) — Madrigal Pharmaceuticals EU Limited

View source ↗

Summary

EMA authorised Rezdiffra (resmetirom) for non-alcoholic fatty liver disease and cirrhosis of the liver, granted with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• REZDIFFRA (RESMETIROM)

Snippet

Status: Authorised. Therapeutic area: Non-alcoholic Fatty Liver Disease;Liver Cirrhosis. MAH: Madrigal Pharmaceuticals EU Limited. Decision date: 18/08/2025. Conditional approval